Healthcare utilization and cost burden of Huntington's disease among Medicare beneficiaries in the United States
To examine healthcare utilization and costs in a US Medicare population diagnosed with Huntington's disease (HD). This was a retrospective matched cohort study using Medicare fee-for-service (FFS) claims data using 2013-2017 Research Identifiable Files. Medicare beneficiaries diagnosed with HD...
Gespeichert in:
| Veröffentlicht in: | Journal of medical economics 2021-01, Vol.24 (1), p.1327-1336 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1336 |
|---|---|
| container_issue | 1 |
| container_start_page | 1327 |
| container_title | Journal of medical economics |
| container_volume | 24 |
| creator | Exuzides, Alex Reddy, Sheila R. Chang, Eunice Ta, Jamie T. Patel, Anisha M. Paydar, Caleb Yohrling, George J. |
| description | To examine healthcare utilization and costs in a US Medicare population diagnosed with Huntington's disease (HD).
This was a retrospective matched cohort study using Medicare fee-for-service (FFS) claims data using 2013-2017 Research Identifiable Files. Medicare beneficiaries diagnosed with HD based on the presence of at least one medical claim with an International Classification of Diseases, Ninth or Tenth Revision, Clinical Modification (ICD-9/10-CM) diagnosis code for HD (ICD-9-CM: 333.4; ICD-10-CM: G10) during the identification period (2014-2016). Beneficiaries without HD were drawn from a 5% random sample of Medicare beneficiaries and 1:1 matched to those with HD for comparison. All-cause and HD-related (any utilization related to HD diagnosis or symptoms associated with HD) healthcare utilization and costs were reported.
We identified 3,688 matched pairs of beneficiaries with and without HD. Of those with HD, 1,922 (52.1%) were late-stage, 916 (24.8%) were middle-stage, and 850 (23.1%) were early-stage. Mean [SD] annual total healthcare costs were higher for HD beneficiaries than beneficiaries without HD ($41,631 [57,393] vs. $17,222 [31,218], p |
| doi_str_mv | 10.1080/13696998.2021.2002579 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_13696998_2021_2002579</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2593029499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-2dc3b68e06ea65848189fc05d505fc6f3a06543ad9fe1577dc419aa88031ad223</originalsourceid><addsrcrecordid>eNp9kMFO3DAQhq2KqiDKI7TyjV6yteM4sW-tEHQrUfXQIvVmzdpjcJXYi-0IwdM3yy49MoeZOXz_jPQR8oGzFWeKfeai173WatWyli-NtXLQb8gJ1x1vlBj-HC37wjQ76JiclfKXLSUEZwN_R45FNwjWDcMJ2a4RxnpnISOdaxjDE9SQIoXoqE2l0s2cHUaaPF3PsYZ4W1M8L9SFglCQwpTiLf2BLjyf2GBEH2yAHLDQEGm9Q3oTQ0VHf1WoWN6Ttx7GgmeHeUpuri5_X6yb65_fvl98vW5sx0VtWmfFplfIeoReqk5xpb1l0kkmve29ANbLToDTHrkcBrfENIBSTHBwbStOyaf93W1O9zOWaqZQLI4jRExzMa3UgrW603pB5R61OZWS0ZttDhPkR8OZ2fk2L77Nzrc5-F5yHw8v5s2E7n_qxe4CfNkDIfqUJ3hIeXSmwuOYss8QbShGvP7jH7yLkAE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2593029499</pqid></control><display><type>article</type><title>Healthcare utilization and cost burden of Huntington's disease among Medicare beneficiaries in the United States</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Exuzides, Alex ; Reddy, Sheila R. ; Chang, Eunice ; Ta, Jamie T. ; Patel, Anisha M. ; Paydar, Caleb ; Yohrling, George J.</creator><creatorcontrib>Exuzides, Alex ; Reddy, Sheila R. ; Chang, Eunice ; Ta, Jamie T. ; Patel, Anisha M. ; Paydar, Caleb ; Yohrling, George J.</creatorcontrib><description>To examine healthcare utilization and costs in a US Medicare population diagnosed with Huntington's disease (HD).
This was a retrospective matched cohort study using Medicare fee-for-service (FFS) claims data using 2013-2017 Research Identifiable Files. Medicare beneficiaries diagnosed with HD based on the presence of at least one medical claim with an International Classification of Diseases, Ninth or Tenth Revision, Clinical Modification (ICD-9/10-CM) diagnosis code for HD (ICD-9-CM: 333.4; ICD-10-CM: G10) during the identification period (2014-2016). Beneficiaries without HD were drawn from a 5% random sample of Medicare beneficiaries and 1:1 matched to those with HD for comparison. All-cause and HD-related (any utilization related to HD diagnosis or symptoms associated with HD) healthcare utilization and costs were reported.
We identified 3,688 matched pairs of beneficiaries with and without HD. Of those with HD, 1,922 (52.1%) were late-stage, 916 (24.8%) were middle-stage, and 850 (23.1%) were early-stage. Mean [SD] annual total healthcare costs were higher for HD beneficiaries than beneficiaries without HD ($41,631 [57,393] vs. $17,222 [31,218], p < .001) and were primarily driven by outpatient pharmacy costs ($19,182 [45,469] vs. $4,318 [11,553], p < .001). In the stratified analysis, total healthcare costs were highest among beneficiaries with late-stage HD (mean [SD] cost: $20,475 [$41,122] for early-stage vs. $29,733 [$44,977] for middle-stage vs. $56,657 [$64,185] for late-stage; p < .001).
Results are not generalizable to beneficiaries enrolled in other non-FFS Medicare plans. Administrative claims are intended for billing purposes, not research, and may not capture all symptoms, comorbidities, and other adverse events.
This original, comprehensive analysis of healthcare utilization and economic burden among Medicare beneficiaries with HD found that healthcare needs and associated costs are substantially higher among Medicare beneficiaries who are diagnosed with HD compared to beneficiaries without HD.</description><identifier>ISSN: 1369-6998</identifier><identifier>EISSN: 1941-837X</identifier><identifier>DOI: 10.1080/13696998.2021.2002579</identifier><identifier>PMID: 34730477</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>administrative claims ; Aged ; Cohort Studies ; Delivery of Health Care ; Health Care Costs ; healthcare utilization and cost burden ; Humans ; Huntington Disease ; Huntington's disease ; ICD-10-CM: G10 ; ICD-9-CM: 333.4 ; Medicare ; Patient Acceptance of Health Care ; Retrospective Studies ; United States</subject><ispartof>Journal of medical economics, 2021-01, Vol.24 (1), p.1327-1336</ispartof><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-2dc3b68e06ea65848189fc05d505fc6f3a06543ad9fe1577dc419aa88031ad223</citedby><cites>FETCH-LOGICAL-c413t-2dc3b68e06ea65848189fc05d505fc6f3a06543ad9fe1577dc419aa88031ad223</cites><orcidid>0000-0001-9971-9485</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.2002579$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/13696998.2021.2002579$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,27479,27901,27902,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34730477$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Exuzides, Alex</creatorcontrib><creatorcontrib>Reddy, Sheila R.</creatorcontrib><creatorcontrib>Chang, Eunice</creatorcontrib><creatorcontrib>Ta, Jamie T.</creatorcontrib><creatorcontrib>Patel, Anisha M.</creatorcontrib><creatorcontrib>Paydar, Caleb</creatorcontrib><creatorcontrib>Yohrling, George J.</creatorcontrib><title>Healthcare utilization and cost burden of Huntington's disease among Medicare beneficiaries in the United States</title><title>Journal of medical economics</title><addtitle>J Med Econ</addtitle><description>To examine healthcare utilization and costs in a US Medicare population diagnosed with Huntington's disease (HD).
This was a retrospective matched cohort study using Medicare fee-for-service (FFS) claims data using 2013-2017 Research Identifiable Files. Medicare beneficiaries diagnosed with HD based on the presence of at least one medical claim with an International Classification of Diseases, Ninth or Tenth Revision, Clinical Modification (ICD-9/10-CM) diagnosis code for HD (ICD-9-CM: 333.4; ICD-10-CM: G10) during the identification period (2014-2016). Beneficiaries without HD were drawn from a 5% random sample of Medicare beneficiaries and 1:1 matched to those with HD for comparison. All-cause and HD-related (any utilization related to HD diagnosis or symptoms associated with HD) healthcare utilization and costs were reported.
We identified 3,688 matched pairs of beneficiaries with and without HD. Of those with HD, 1,922 (52.1%) were late-stage, 916 (24.8%) were middle-stage, and 850 (23.1%) were early-stage. Mean [SD] annual total healthcare costs were higher for HD beneficiaries than beneficiaries without HD ($41,631 [57,393] vs. $17,222 [31,218], p < .001) and were primarily driven by outpatient pharmacy costs ($19,182 [45,469] vs. $4,318 [11,553], p < .001). In the stratified analysis, total healthcare costs were highest among beneficiaries with late-stage HD (mean [SD] cost: $20,475 [$41,122] for early-stage vs. $29,733 [$44,977] for middle-stage vs. $56,657 [$64,185] for late-stage; p < .001).
Results are not generalizable to beneficiaries enrolled in other non-FFS Medicare plans. Administrative claims are intended for billing purposes, not research, and may not capture all symptoms, comorbidities, and other adverse events.
This original, comprehensive analysis of healthcare utilization and economic burden among Medicare beneficiaries with HD found that healthcare needs and associated costs are substantially higher among Medicare beneficiaries who are diagnosed with HD compared to beneficiaries without HD.</description><subject>administrative claims</subject><subject>Aged</subject><subject>Cohort Studies</subject><subject>Delivery of Health Care</subject><subject>Health Care Costs</subject><subject>healthcare utilization and cost burden</subject><subject>Humans</subject><subject>Huntington Disease</subject><subject>Huntington's disease</subject><subject>ICD-10-CM: G10</subject><subject>ICD-9-CM: 333.4</subject><subject>Medicare</subject><subject>Patient Acceptance of Health Care</subject><subject>Retrospective Studies</subject><subject>United States</subject><issn>1369-6998</issn><issn>1941-837X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><recordid>eNp9kMFO3DAQhq2KqiDKI7TyjV6yteM4sW-tEHQrUfXQIvVmzdpjcJXYi-0IwdM3yy49MoeZOXz_jPQR8oGzFWeKfeai173WatWyli-NtXLQb8gJ1x1vlBj-HC37wjQ76JiclfKXLSUEZwN_R45FNwjWDcMJ2a4RxnpnISOdaxjDE9SQIoXoqE2l0s2cHUaaPF3PsYZ4W1M8L9SFglCQwpTiLf2BLjyf2GBEH2yAHLDQEGm9Q3oTQ0VHf1WoWN6Ttx7GgmeHeUpuri5_X6yb65_fvl98vW5sx0VtWmfFplfIeoReqk5xpb1l0kkmve29ANbLToDTHrkcBrfENIBSTHBwbStOyaf93W1O9zOWaqZQLI4jRExzMa3UgrW603pB5R61OZWS0ZttDhPkR8OZ2fk2L77Nzrc5-F5yHw8v5s2E7n_qxe4CfNkDIfqUJ3hIeXSmwuOYss8QbShGvP7jH7yLkAE</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Exuzides, Alex</creator><creator>Reddy, Sheila R.</creator><creator>Chang, Eunice</creator><creator>Ta, Jamie T.</creator><creator>Patel, Anisha M.</creator><creator>Paydar, Caleb</creator><creator>Yohrling, George J.</creator><general>Taylor & Francis</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9971-9485</orcidid></search><sort><creationdate>20210101</creationdate><title>Healthcare utilization and cost burden of Huntington's disease among Medicare beneficiaries in the United States</title><author>Exuzides, Alex ; Reddy, Sheila R. ; Chang, Eunice ; Ta, Jamie T. ; Patel, Anisha M. ; Paydar, Caleb ; Yohrling, George J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-2dc3b68e06ea65848189fc05d505fc6f3a06543ad9fe1577dc419aa88031ad223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>administrative claims</topic><topic>Aged</topic><topic>Cohort Studies</topic><topic>Delivery of Health Care</topic><topic>Health Care Costs</topic><topic>healthcare utilization and cost burden</topic><topic>Humans</topic><topic>Huntington Disease</topic><topic>Huntington's disease</topic><topic>ICD-10-CM: G10</topic><topic>ICD-9-CM: 333.4</topic><topic>Medicare</topic><topic>Patient Acceptance of Health Care</topic><topic>Retrospective Studies</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Exuzides, Alex</creatorcontrib><creatorcontrib>Reddy, Sheila R.</creatorcontrib><creatorcontrib>Chang, Eunice</creatorcontrib><creatorcontrib>Ta, Jamie T.</creatorcontrib><creatorcontrib>Patel, Anisha M.</creatorcontrib><creatorcontrib>Paydar, Caleb</creatorcontrib><creatorcontrib>Yohrling, George J.</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medical economics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Exuzides, Alex</au><au>Reddy, Sheila R.</au><au>Chang, Eunice</au><au>Ta, Jamie T.</au><au>Patel, Anisha M.</au><au>Paydar, Caleb</au><au>Yohrling, George J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Healthcare utilization and cost burden of Huntington's disease among Medicare beneficiaries in the United States</atitle><jtitle>Journal of medical economics</jtitle><addtitle>J Med Econ</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>24</volume><issue>1</issue><spage>1327</spage><epage>1336</epage><pages>1327-1336</pages><issn>1369-6998</issn><eissn>1941-837X</eissn><abstract>To examine healthcare utilization and costs in a US Medicare population diagnosed with Huntington's disease (HD).
This was a retrospective matched cohort study using Medicare fee-for-service (FFS) claims data using 2013-2017 Research Identifiable Files. Medicare beneficiaries diagnosed with HD based on the presence of at least one medical claim with an International Classification of Diseases, Ninth or Tenth Revision, Clinical Modification (ICD-9/10-CM) diagnosis code for HD (ICD-9-CM: 333.4; ICD-10-CM: G10) during the identification period (2014-2016). Beneficiaries without HD were drawn from a 5% random sample of Medicare beneficiaries and 1:1 matched to those with HD for comparison. All-cause and HD-related (any utilization related to HD diagnosis or symptoms associated with HD) healthcare utilization and costs were reported.
We identified 3,688 matched pairs of beneficiaries with and without HD. Of those with HD, 1,922 (52.1%) were late-stage, 916 (24.8%) were middle-stage, and 850 (23.1%) were early-stage. Mean [SD] annual total healthcare costs were higher for HD beneficiaries than beneficiaries without HD ($41,631 [57,393] vs. $17,222 [31,218], p < .001) and were primarily driven by outpatient pharmacy costs ($19,182 [45,469] vs. $4,318 [11,553], p < .001). In the stratified analysis, total healthcare costs were highest among beneficiaries with late-stage HD (mean [SD] cost: $20,475 [$41,122] for early-stage vs. $29,733 [$44,977] for middle-stage vs. $56,657 [$64,185] for late-stage; p < .001).
Results are not generalizable to beneficiaries enrolled in other non-FFS Medicare plans. Administrative claims are intended for billing purposes, not research, and may not capture all symptoms, comorbidities, and other adverse events.
This original, comprehensive analysis of healthcare utilization and economic burden among Medicare beneficiaries with HD found that healthcare needs and associated costs are substantially higher among Medicare beneficiaries who are diagnosed with HD compared to beneficiaries without HD.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>34730477</pmid><doi>10.1080/13696998.2021.2002579</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-9971-9485</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1369-6998 |
| ispartof | Journal of medical economics, 2021-01, Vol.24 (1), p.1327-1336 |
| issn | 1369-6998 1941-837X |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_13696998_2021_2002579 |
| source | Taylor & Francis Open Access; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | administrative claims Aged Cohort Studies Delivery of Health Care Health Care Costs healthcare utilization and cost burden Humans Huntington Disease Huntington's disease ICD-10-CM: G10 ICD-9-CM: 333.4 Medicare Patient Acceptance of Health Care Retrospective Studies United States |
| title | Healthcare utilization and cost burden of Huntington's disease among Medicare beneficiaries in the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T18%3A36%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Healthcare%20utilization%20and%20cost%20burden%20of%20Huntington's%20disease%20among%20Medicare%20beneficiaries%20in%20the%20United%20States&rft.jtitle=Journal%20of%20medical%20economics&rft.au=Exuzides,%20Alex&rft.date=2021-01-01&rft.volume=24&rft.issue=1&rft.spage=1327&rft.epage=1336&rft.pages=1327-1336&rft.issn=1369-6998&rft.eissn=1941-837X&rft_id=info:doi/10.1080/13696998.2021.2002579&rft_dat=%3Cproquest_cross%3E2593029499%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2593029499&rft_id=info:pmid/34730477&rfr_iscdi=true |